Publications by authors named "Steven Gendreau"

Claim this Profile
P
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Dejan Juric, Kyung Song, Radia M Johnson, Melissa K Accordino, Philippe L Bedard, Steven Gendreau

Clin Cancer Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
Kalpit Shah, Matthew H Secrest, Wei Zhou, Shu Wang, Dan Canter, Steven Gendreau

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Xiaoji Chen, Ching-Wei Chang, Jill M Spoerke, Kathryn E Yoh, Vidushi Kapoor, Steven Gendreau

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
Johann S de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, Christophe Massard, Sergio Bracarda, Steven Gendreau

Clin Cancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
Undine Rulle, Zoi Tsourti, Ruben Casanova, Karl-Friedrich Deml, Eric Verbeken, Steven Gendreau

J Thorac Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Travis A Clark, Jon H Chung, Mark Kennedy, Jason D Hughes, Niru Chennagiri, Steven Gendreau

J Mol Diagn· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, Hans Wildiers, Silvia Damian, Steven Gendreau

Breast Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Stephanie B Greene, Angel E Dago, Laura J Leitz, Yipeng Wang, Jerry Lee, Steven Gendreau

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Peter Schmid, Sarah E Pinder, Duncan Wheatley, Jane Macaskill, Charles Zammit, Steven Gendreau

J Clin Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Ian E Krop, Ingrid A Mayer, Vinod Ganju, Maura Dickler, Stephen Johnston, Steven Gendreau

Lancet Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Jill M Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R Wilson

Nat Commun· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Timothy Forsyth, Patrick C Kearney, Byung Gyu Kim, Henry W B Johnson, Naing Aay, Steven B Gendreau

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Torsten Trowe, Sotiria Boukouvala, Keith Calkins, Richard E Cutler, Ryan Fong, Steven B Gendreau

Clin Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Steven B Gendreau, Richard Ventura, Paul Keast, A Douglas Laird, F Michael Yakes

Clin Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential embryonic roles of the CKI-1 cyclin-dependent kinase inhibitor in cell-cycle exit and morphogenesis in C elegans.
Masamitsu Fukuyama, Steven B Gendreau, W Brent Derry, Joel H Rothman

Dev Biol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis